-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Downgrades Verona Pharma to Hold, Announces $107 Price Target

Benzinga·07/09/2025 19:55:03
Listen to the news
Canaccord Genuity analyst Edward Nash downgrades Verona Pharma (NASDAQ:VRNA) from Buy to Hold and announces $107 price target.